PRESS RELEASE published on 12/09/2025 at 14:50, 6 months 18 days ago Informations privilégiées / Autres communiqués Teva Pharmaceuticals dépose une demande d'autorisation de mise sur le marché pour Olanzapine LAI, traitement mensuel de la schizophrénie chez l'adulte. Medincell, société de licensing biopharmaceutique, développe des traitements injectables à action prolongée Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI Traitement Injectable
PRESS RELEASE published on 12/09/2025 at 14:50, 6 months 18 days ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 7 months 17 days ago Medincell élargit le rôle du Dr Grace Kim pour stimuler la croissance du capital américain Biotechnologie Medincell Stratégie Pharmaceutique Dr Grace Kim Croissance Du Capital Américain
BRIEF published on 11/11/2025 at 08:05, 7 months 17 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 7 months 17 days ago Informations privilégiées / Autres communiqués Medincell nomme le Dr Grace Kim au poste de Chief Strategy Officer, U.S. Finance, pour renforcer la croissance de son capital aux États-Unis. Découvrez son parcours et son rôle clé chez Medincell Croissance Chief Strategy Officer Medincell Dr Grace Kim Capital Américain
PRESS RELEASE published on 11/11/2025 at 08:00, 7 months 17 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 7 months 22 days ago Croissance continue pour Medincell et nouvelles perspectives avec l'Olanzapine LAI Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
BRIEF published on 11/05/2025 at 13:51, 7 months 22 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 7 months 22 days ago Informations privilégiées / Autres communiqués Medincell annonce la poursuite de la croissance d'UZEDY® et la préparation du dépôt de l'Olanzapine LAI sur le marché américain par Teva Pharmaceuticals Croissance Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 7 months 22 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
Published on 06/27/2026 at 16:50, 16 hours 53 minutes ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 8 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 9 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 10 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 10 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/27/2026 at 00:05, 1 day 9 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 9 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 10 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 10 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 10 hours ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
